Commentary on "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial" by Gautret et al.
Level 5 - mechanism / opinion, no new human data
Commentary and narrative methodological review of a single study with no new human data.
PubMed 32537099 · doi:10.1080/20016689.2020.1758390
What was done
Methodological commentary evaluating the open-label, non-randomized clinical trial by Gautret et al. on hydroxychloroquine with or without azithromycin versus standard of care for COVID-19. The authors assessed study validity, contextualized findings with early reports from China and South Korea, and evaluated public health policy implications based on the abstract.
What was found
No quantitative results, sample sizes, or numerical effect estimates are provided in the abstract. The commentary identified several methodological flaws in the Gautret et al. trial, including small sample size, lack of comparability between treatment and control groups, absence of blinding, interim analyses conducted without controlling for type 1 error, use of per-protocol rather than intention-to-treat analysis, and protocol-to-publication discrepancies. The authors noted that none of these observations reversed the study's conclusions.
Why it matters
This commentary illustrates early-pandemic scientific debates regarding the evidentiary threshold required for public health decisions during the rapid emergence of COVID-19.
Limits
This is a narrative commentary presenting expert opinion without original clinical data or systematic review methodology. The single study evaluated was non-randomized, open-label, and subject to multiple severe methodological limitations.
Cited by
- context A 32-patient open-label clinical trial found 70% of hydroxychloroquine-treated COVID-19 patients cleared the virus by day 6 compared to 12.5% in the control group, and 100% cleared when combined with azithromycin.